Experimental Stomach Cancer Drug Sone-Ve Doubles Survival After Multiple Prior Treatments

Patients with advanced, treatment-resistant stomach cancer face limited options, and about 36% of Sone-Ve patients reported serious side effects, mainly gastrointestinal problems.
Ten months on Sone-Ve, five on standard care
Median survival for patients who had already had at least two prior treatments in the CLARITY-Gastric01 trial.
Mark

So what is the headline here? Survival doubled?

Mimi

In one group, yes: people who'd had at least two prior treatments lived a median of 10 months on Sone-Ve versus 5 on standard care.

Luke

Worth noting that's a median, and it's a subgroup. Across everyone it was 10.6 versus 6.4 months, a smaller gap.

Mark

And the cancer didn't stay controlled longer?

Mimi

Right. Progression-free survival, the second main goal, showed no clear advantage for Sone-Ve.

Luke

Which makes the survival result harder to interpret. The source doesn't explain why people lived longer without a clear progression benefit.

Mark

What about people getting it as a second treatment?

Mimi

No clear survival advantage there. Dr. Janjigian still wants earlier access because patients can get too weak for later therapy.

Luke

That's her clinical judgment, not trial evidence. Prof. Al-Batran called second-line use less certain, though he said safety is manageable.

Mark

And safety?

Mimi

Serious side effects were about 36% versus 45% on standard care, but serious gut problems were more common with Sone-Ve.

Luke

Also unknown: how it performs after zolbetuximab, since few participants had received it. CLARITY-Gastric02 may tell us more about first-line use.

  • A heavily pretreated stomach cancer population is running out of options, and every month of survival carries real weight.
  • Sone-Ve, an antibody-drug conjugate aimed at claudin 18.2, is landing with cautious hope as trial results reach the ESMO 2026 stage.
  • Among patients with at least two prior treatments, median survival reached 10 months versus 5 on standard care, a striking gap that clinicians are weighing carefully.
  • Progression-free survival and second-line results did not show a clear advantage, leaving experts divided on how far the benefit extends.
  • Side effects, mainly gastrointestinal, remain a burden, yet serious events were somewhat less frequent than with standard chemotherapy.
  • The next step, CLARITY-Gastric02, is testing the drug as a first treatment to see whether earlier use changes the outcome.

Stomach cancer that has grown through earlier treatment has long offered patients few paths, and a new experimental medicine, Sone-Ve, offers a measured sign of change. Its benefit appears most clearly in people who have already tried several therapies, where it extended median survival from about five months to ten, though the wider picture is more tentative. Whether it will matter in earlier stages, and for those who have not yet been treated, depends on research still underway.

At the ESMO 2026 meeting, researchers presented results for an experimental drug called Sone-Ve, short for sonesitatug vedotin, in people whose advanced stomach cancer kept growing after treatment. Among those who had already endured at least two earlier treatments, median survival was 10 months on Sone-Ve compared with 5 months on standard care.

Sone-Ve pairs an antibody, which seeks out a protein called claudin 18.2 on some stomach cancer cells, with a powerful chemotherapy agent, MMAE. The idea is to deliver the chemo directly to the tumor and spare more healthy cells than conventional chemotherapy does. Across the full trial population of 532 patients, survival was 10.6 months versus 6.4, though the drug did not clearly slow the cancer's growth, and the picture was less convincing for patients receiving it as a second treatment.

Dr. Janjigian, who has treated patients with the drug for years, argues for earlier access, noting that many patients decline quickly and some are too weak for later lines of therapy. Other experts, including Prof. Al-Batran, urge caution. Side effects such as nausea, vomiting, loss of appetite, and nerve damage are real, but serious adverse events occurred in about 36 percent of Sone-Ve patients versus 45 percent on standard treatment.

Sone-Ve is not yet approved outside trials. For patients now, the practical steps are testing the tumor for claudin 18.2, asking about clinical trial options, and planning ahead for what comes next if treatment stops working.

At the ESMO 2026 meeting, researchers presented results for an experimental drug called Sone-Ve, short for sonesitatug vedotin, in people whose advanced stomach cancer had kept growing after treatment. In the group that had already been through at least two earlier treatments, median overall survival was 10 months on Sone-Ve and 5 months on standard care.

Sone-Ve is an antibody-drug conjugate. One part is an antibody, a lab-made protein that seeks out a protein called claudin 18.2 on the surface of some stomach cancer cells. Attached to it is a strong chemotherapy agent, MMAE (monomethyl auristatin E). The antibody carries the chemo to the tumor, with the aim of hitting cancer hard while sparing more healthy cells than regular chemotherapy does. One approved drug already targets claudin 18.2: zolbetuximab, sold as Vyloy, which is given with chemotherapy as a first treatment. Doctors find out whether a tumor carries the protein by testing a tumor sample in a lab.

The trial, CLARITY-Gastric01, was a phase 3 study, the large, late-stage kind usually needed before approval. Its main comparison included 532 people with stomach cancer or cancer at the junction of the esophagus and stomach. Their disease had spread or could not be removed surgically, and had progressed after at least one earlier treatment. They were randomly assigned to Sone-Ve or to a standard treatment chosen by their doctor, such as paclitaxel, docetaxel or irinotecan. To enroll, at least 25% of tumor cells had to show claudin 18.2, a lower threshold than the one used for zolbetuximab, so more patients may qualify.

Across everyone in the study, people on Sone-Ve lived a median of 10.6 months versus 6.4 months on standard treatment. But the study had a second main goal, progression-free survival, meaning time alive without the cancer growing, and there Sone-Ve did not clearly beat standard care. The survival benefit held whether a tumor had a moderate or high amount of claudin 18.2.

The picture is murkier for people receiving Sone-Ve as a second treatment. Looking only at that group, researchers found no clear survival advantage. Dr. Janjigian, who has treated patients with the drug for several years, still argues for earlier access. Many patients decline quickly once initial treatment fails, she said, and by third-line therapy some are too weak to continue. "I absolutely think these results are practice changing," she said. Prof. Salah-Eddin Al-Batran of the University Cancer Center Frankfurt, in comments published by ESMO, was more cautious: the second-line situation is less certain given the lack of a significant difference in progression-free survival, though the safety profile is manageable.

Side effects follow the drug's design. Janjigian described gastrointestinal problems, particularly nausea, vomiting and decreased appetite, which matter in a disease where many patients already struggle with nutrition and weight loss. The chemotherapy component can lower blood counts and cause peripheral neuropathy, nerve damage that brings numbness, tingling or pain in the hands and feet. She said these are generally manageable with supportive care and dose adjustments. Overall, serious side effects were somewhat less common with Sone-Ve, about 36% of patients versus about 45% on standard treatment. Serious stomach and gut problems were more common with Sone-Ve, while serious drops in blood counts were more common with standard care.

Sone-Ve remains experimental and is not approved outside clinical trials. It is also unclear how well it works after zolbetuximab, since relatively few patients in the study had received that drug. A new study, CLARITY-Gastric02, is testing Sone-Ve as a first treatment. For patients with advanced stomach cancer, the practical questions are whether their tumor has been tested for claudin 18.2, whether a clinical trial is an option, and what the plan is if the current treatment stops working.

I absolutely think these results are practice changing.
— Dr. Janjigian
The situation in the second-line setting is less certain given the lack of a significant difference in PFS, but the safety profile is manageable.
— Prof. Salah-Eddin Al-Batran, University Cancer Center Frankfurt
Contattaci Domande frequenti